Amring, a niche generic and brand pharmaceutical company, has joined The End Drug Shortages Alliance, a new coalition of diverse stakeholders formed to address drug shortages in the United States.
[Read more: Amring intros generic Lamictal]
“Drug shortages continue to impact health care and its delivery,” said Daniel Carbery, president and CEO of Amring. “As a member of Alliance, we will work together to develop collaborative mitigation strategies to address issues contributing to these shortages.”
Alliance launched in late 2021 to bring together industry stakeholders, including providers, group purchasing organizations, manufacturers, distributors, and other industry thought leaders and champions. Efforts will focus on improving access to medications through greater transparency across market participants, leading to improved quality manufacturing of medications and production of additional supply, the organization said.
[Read more: Amring gets FDA blessing for generic Isuprel]
“We are grateful to have Amring join Alliance to end drug shortages,” said Eric Tichy, division chair of Pharmacy Supply Solutions at the Mayo Clinic, who serves as the chair for the alliance advisory board.
“Collaboration among organizations strengthens our ability to improve the quality of life for patients that rely on these medications,” Tichy said. “Together, we can make a difference.”